Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Interest Expenses (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Interest Expenses for 7 consecutive years, with $11.6 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 45.93% to $11.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103.2 million through Dec 2025, up 13.37% year-over-year, with the annual reading at $53.1 million for FY2025, 41.64% down from the prior year.
  • Interest Expenses hit $11.6 million in Q4 2025 for BridgeBio Pharma, down from $11.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $42.1 million in Q1 2025 to a low of $9.7 million in Q1 2021.
  • Historically, Interest Expenses has averaged $20.1 million across 5 years, with a median of $20.3 million in 2022.
  • Biggest five-year swings in Interest Expenses: skyrocketed 142.84% in 2021 and later crashed 49.1% in 2025.
  • Year by year, Interest Expenses stood at $15.1 million in 2021, then surged by 32.09% to $20.0 million in 2022, then grew by 1.39% to $20.3 million in 2023, then grew by 6.19% to $21.5 million in 2024, then plummeted by 45.93% to $11.6 million in 2025.
  • Business Quant data shows Interest Expenses for BBIO at $11.6 million in Q4 2025, $11.7 million in Q3 2025, and $37.6 million in Q2 2025.